Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 453 entries
Sorted by: Best Match Show Resources per page
The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma.

Therapeutic advances in urology

Borregales LD, Adibi M, Thomas AZ, Wood CG, Karam JA.
PMID: 27034725
Ther Adv Urol. 2016 Apr;8(2):130-41. doi: 10.1177/1756287215612962. Epub 2015 Nov 20.

In the past decade, the armamentarium of targeted therapy agents for the treatment of metastatic renal cell carcinoma (RCC) has significantly increased. Improvements in response rates and survival, with more manageable side effects compared with interleukin 2/interferon immunotherapy, have...

Cite
Borregales LD, Adibi M, Thomas AZ, et al. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol. 2015;8(2):130-41doi: 10.1177/1756287215612962.
Borregales, L. D., Adibi, M., Thomas, A. Z., Wood, C. G., & Karam, J. A. (2016). The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Therapeutic advances in urology, 8(2), 130-41. https://doi.org/10.1177/1756287215612962
Borregales, Leonardo D, et al. "The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma." Therapeutic advances in urology vol. 8,2 (2016): 130-41. doi: https://doi.org/10.1177/1756287215612962
Borregales LD, Adibi M, Thomas AZ, Wood CG, Karam JA. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol. 2016 Apr;8(2):130-41. doi: 10.1177/1756287215612962. Epub 2015 Nov 20. PMID: 27034725; PMCID: PMC4772353.
Copy Download .nbib Format: NLM
Is whole gland salvage cryotherapy effective as palliative treatment of haematuria in patients with locally advanced prostate cancer? Results of a preliminary case series.

Therapeutic advances in urology

Magno C, Mucciardi G, Galì A, Pappalardo R, Lembo F, Anastasi G, Butticè S, Ascenti G, Lugnani F.
PMID: 26425138
Ther Adv Urol. 2015 Oct;7(5):235-40. doi: 10.1177/1756287215585451.

OBJECTIVES: Locally advanced prostate cancer may cause several complications such as haematuria, bladder outlet obstruction, and renal failure due to the ureteral obstruction. Various treatments have been suggested, including radiotherapy, antifibrinolytics, bladder irrigation with alum solution, transurethral surgery and...

Cite
Magno C, Mucciardi G, Galì A, et al. Is whole gland salvage cryotherapy effective as palliative treatment of haematuria in patients with locally advanced prostate cancer? Results of a preliminary case series. Ther Adv Urol. 2015;7(5):235-40doi: 10.1177/1756287215585451.
Magno, C., Mucciardi, G., Galì, A., Pappalardo, R., Lembo, F., Anastasi, G., Butticè, S., Ascenti, G., & Lugnani, F. (2015). Is whole gland salvage cryotherapy effective as palliative treatment of haematuria in patients with locally advanced prostate cancer? Results of a preliminary case series. Therapeutic advances in urology, 7(5), 235-40. https://doi.org/10.1177/1756287215585451
Magno, Carlo, et al. "Is whole gland salvage cryotherapy effective as palliative treatment of haematuria in patients with locally advanced prostate cancer? Results of a preliminary case series." Therapeutic advances in urology vol. 7,5 (2015): 235-40. doi: https://doi.org/10.1177/1756287215585451
Magno C, Mucciardi G, Galì A, Pappalardo R, Lembo F, Anastasi G, Butticè S, Ascenti G, Lugnani F. Is whole gland salvage cryotherapy effective as palliative treatment of haematuria in patients with locally advanced prostate cancer? Results of a preliminary case series. Ther Adv Urol. 2015 Oct;7(5):235-40. doi: 10.1177/1756287215585451. PMID: 26425138; PMCID: PMC4549698.
Copy Download .nbib Format: NLM
Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.

Therapeutic advances in urology

Culp SH.
PMID: 26425142
Ther Adv Urol. 2015 Oct;7(5):275-85. doi: 10.1177/1756287215585501.

The beneficial effect of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma in the immunotherapy era was based on two prospective randomized trials. Unfortunately, such evidence does not yet exist in the present-day period of targeted...

Cite
Culp SH. Cytoreductive nephrectomy and its role in the present-day period of targeted therapy. Ther Adv Urol. 2015;7(5):275-85doi: 10.1177/1756287215585501.
Culp, S. H. (2015). Cytoreductive nephrectomy and its role in the present-day period of targeted therapy. Therapeutic advances in urology, 7(5), 275-85. https://doi.org/10.1177/1756287215585501
Culp, Stephen H. "Cytoreductive nephrectomy and its role in the present-day period of targeted therapy." Therapeutic advances in urology vol. 7,5 (2015): 275-85. doi: https://doi.org/10.1177/1756287215585501
Culp SH. Cytoreductive nephrectomy and its role in the present-day period of targeted therapy. Ther Adv Urol. 2015 Oct;7(5):275-85. doi: 10.1177/1756287215585501. PMID: 26425142; PMCID: PMC4549699.
Copy Download .nbib Format: NLM
Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence.

Therapeutic advances in urology

Aoun F, Bourgi A, Ayoub E, El Rassy E, van Velthoven R, Peltier A.
PMID: 28392836
Ther Adv Urol. 2017 Mar 01;9(3):73-80. doi: 10.1177/1756287217697661. eCollection 2017.

Following new scientific insights, initial management for patients with high-risk nonmetastatic prostate cancer has changed considerably and rapidly over the last few years. Several clinical and pathologic variables should be taken into account when deciding the best treatment choice...

Cite
Aoun F, Bourgi A, Ayoub E, et al. Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence. Ther Adv Urol. 2017;9(3):73-80doi: 10.1177/1756287217697661.
Aoun, F., Bourgi, A., Ayoub, E., El Rassy, E., van Velthoven, R., & Peltier, A. (2017). Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence. Therapeutic advances in urology, 9(3), 73-80. https://doi.org/10.1177/1756287217697661
Aoun, Fouad, et al. "Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence." Therapeutic advances in urology vol. 9,3 (2017): 73-80. doi: https://doi.org/10.1177/1756287217697661
Aoun F, Bourgi A, Ayoub E, El Rassy E, van Velthoven R, Peltier A. Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence. Ther Adv Urol. 2017 Mar 01;9(3):73-80. doi: 10.1177/1756287217697661. eCollection 2017. PMID: 28392836; PMCID: PMC5378097.
Copy Download .nbib Format: NLM
A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction.

Therapeutic advances in urology

Hatzimouratidis K.
PMID: 25083163
Ther Adv Urol. 2014 Aug;6(4):135-47. doi: 10.1177/1756287214531639.

Epidemiological data link erectile dysfunction (ED) and benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS), two highly prevalent conditions in aging men, assuming common pathophysiological pathways. Tadalafil 5 mg once daily has been approved for the treatment of...

Cite
Hatzimouratidis K. A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction. Ther Adv Urol. 2014;6(4):135-47doi: 10.1177/1756287214531639.
Hatzimouratidis, K. (2014). A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction. Therapeutic advances in urology, 6(4), 135-47. https://doi.org/10.1177/1756287214531639
Hatzimouratidis, Konstantinos. "A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction." Therapeutic advances in urology vol. 6,4 (2014): 135-47. doi: https://doi.org/10.1177/1756287214531639
Hatzimouratidis K. A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction. Ther Adv Urol. 2014 Aug;6(4):135-47. doi: 10.1177/1756287214531639. PMID: 25083163; PMCID: PMC4054509.
Copy Download .nbib Format: NLM
Best practice in the assessment of bladder function in infants.

Therapeutic advances in urology

Guerra L, Leonard M, Castagnetti M.
PMID: 25083164
Ther Adv Urol. 2014 Aug;6(4):148-64. doi: 10.1177/1756287214528745.

The purpose of this article is to review normal developmental bladder physiology in infants and bladder dysfunction in conditions such as neurogenic bladder, posterior urethral valves and high grade vesicoureteric reflux. We contrast the classical concept that bladder function...

Cite
Guerra L, Leonard M, Castagnetti M. Best practice in the assessment of bladder function in infants. Ther Adv Urol. 2014;6(4):148-64doi: 10.1177/1756287214528745.
Guerra, L., Leonard, M., & Castagnetti, M. (2014). Best practice in the assessment of bladder function in infants. Therapeutic advances in urology, 6(4), 148-64. https://doi.org/10.1177/1756287214528745
Guerra, Luis, et al. "Best practice in the assessment of bladder function in infants." Therapeutic advances in urology vol. 6,4 (2014): 148-64. doi: https://doi.org/10.1177/1756287214528745
Guerra L, Leonard M, Castagnetti M. Best practice in the assessment of bladder function in infants. Ther Adv Urol. 2014 Aug;6(4):148-64. doi: 10.1177/1756287214528745. PMID: 25083164; PMCID: PMC4054507.
Copy Download .nbib Format: NLM
Innovations in the management of Wilms' tumor.

Therapeutic advances in urology

Gleason JM, Lorenzo AJ, Bowlin PR, Koyle MA.
PMID: 25083165
Ther Adv Urol. 2014 Aug;6(4):165-76. doi: 10.1177/1756287214528023.

Advances in the management of Wilms' tumor have been dramatic over the past half century, not in small part due to the institution of multimodal therapy and the formation of collaborative study groups. While different opinions exist in the...

Cite
Gleason JM, Lorenzo AJ, Bowlin PR, et al. Innovations in the management of Wilms' tumor. Ther Adv Urol. 2014;6(4):165-76doi: 10.1177/1756287214528023.
Gleason, J. M., Lorenzo, A. J., Bowlin, P. R., & Koyle, M. A. (2014). Innovations in the management of Wilms' tumor. Therapeutic advances in urology, 6(4), 165-76. https://doi.org/10.1177/1756287214528023
Gleason, Joseph M, et al. "Innovations in the management of Wilms' tumor." Therapeutic advances in urology vol. 6,4 (2014): 165-76. doi: https://doi.org/10.1177/1756287214528023
Gleason JM, Lorenzo AJ, Bowlin PR, Koyle MA. Innovations in the management of Wilms' tumor. Ther Adv Urol. 2014 Aug;6(4):165-76. doi: 10.1177/1756287214528023. PMID: 25083165; PMCID: PMC4054506.
Copy Download .nbib Format: NLM
Desmopressin in the treatment of nocturia: clinical evidence and experience.

Therapeutic advances in urology

Friedman FM, Weiss JP.
PMID: 24294289
Ther Adv Urol. 2013 Dec;5(6):310-7. doi: 10.1177/1756287213502116.

Nocturia is a common and bothersome condition experienced by both men and women. Studies have suggested that nocturia contributes a level of morbidity to those who suffer from the condition, both young and old. Desmopressin has historically been utilized...

Cite
Friedman FM, Weiss JP. Desmopressin in the treatment of nocturia: clinical evidence and experience. Ther Adv Urol. 2013;5(6):310-7doi: 10.1177/1756287213502116.
Friedman, F. M., & Weiss, J. P. (2013). Desmopressin in the treatment of nocturia: clinical evidence and experience. Therapeutic advances in urology, 5(6), 310-7. https://doi.org/10.1177/1756287213502116
Friedman, Fara M, and Weiss, Jeffrey P. "Desmopressin in the treatment of nocturia: clinical evidence and experience." Therapeutic advances in urology vol. 5,6 (2013): 310-7. doi: https://doi.org/10.1177/1756287213502116
Friedman FM, Weiss JP. Desmopressin in the treatment of nocturia: clinical evidence and experience. Ther Adv Urol. 2013 Dec;5(6):310-7. doi: 10.1177/1756287213502116. PMID: 24294289; PMCID: PMC3825109.
Copy Download .nbib Format: NLM
Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials.

Therapeutic advances in urology

Kaushik D, Vashistha V, Isharwal S, Sediqe SA, Lin MF.
PMID: 26622323
Ther Adv Urol. 2015 Dec;7(6):388-95. doi: 10.1177/1756287215597637.

Historically, androgen-deprivation therapy has been the cornerstone for treatment of metastatic prostate cancer. Unfortunately, nearly majority patients with prostate cancer transition to the refractory state of castration-resistant prostate cancer (CRPC). Newer therapeutic agents are needed for treating these CRPC...

Cite
Kaushik D, Vashistha V, Isharwal S, et al. Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. Ther Adv Urol. 2015;7(6):388-95doi: 10.1177/1756287215597637.
Kaushik, D., Vashistha, V., Isharwal, S., Sediqe, S. A., & Lin, M. F. (2015). Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. Therapeutic advances in urology, 7(6), 388-95. https://doi.org/10.1177/1756287215597637
Kaushik, Dharam, et al. "Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials." Therapeutic advances in urology vol. 7,6 (2015): 388-95. doi: https://doi.org/10.1177/1756287215597637
Kaushik D, Vashistha V, Isharwal S, Sediqe SA, Lin MF. Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. Ther Adv Urol. 2015 Dec;7(6):388-95. doi: 10.1177/1756287215597637. PMID: 26622323; PMCID: PMC4647138.
Copy Download .nbib Format: NLM
Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study.

Therapeutic advances in urology

Pagliarulo V, Ancona P, Martines I, Spadavecchia R, Di Stasi S, Alba S, Cormio L, Fanizza C, Salerno A, Carrieri G, Pagliarulo A.
PMID: 26622316
Ther Adv Urol. 2015 Dec;7(6):303-11. doi: 10.1177/1756287215599695.

OBJECTIVES: New targets and approaches are under investigation for the treatment of nonmuscle invasive bladder cancer (NMIBC). Preclinical data suggest cyclooxygenase-2 (COX-2) as a promising target. Celecoxib, a COX-2 selective inhibitor, inhibits tumor development and enhances survival, both in...

Cite
Pagliarulo V, Ancona P, Martines I, et al. Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study. Ther Adv Urol. 2015;7(6):303-11doi: 10.1177/1756287215599695.
Pagliarulo, V., Ancona, P., Martines, I., Spadavecchia, R., Di Stasi, S., Alba, S., Cormio, L., Fanizza, C., Salerno, A., Carrieri, G., & Pagliarulo, A. (2015). Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study. Therapeutic advances in urology, 7(6), 303-11. https://doi.org/10.1177/1756287215599695
Pagliarulo, Vincenzo, et al. "Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study." Therapeutic advances in urology vol. 7,6 (2015): 303-11. doi: https://doi.org/10.1177/1756287215599695
Pagliarulo V, Ancona P, Martines I, Spadavecchia R, Di Stasi S, Alba S, Cormio L, Fanizza C, Salerno A, Carrieri G, Pagliarulo A. Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study. Ther Adv Urol. 2015 Dec;7(6):303-11. doi: 10.1177/1756287215599695. PMID: 26622316; PMCID: PMC4647141.
Copy Download .nbib Format: NLM
Diseases masking and delaying the diagnosis of urogenital tuberculosis.

Therapeutic advances in urology

Altez-Fernandez C, Seas C, Zegarra L, Ugarte-Gil C.
PMID: 27247632
Ther Adv Urol. 2016 Jun;8(3):234. doi: 10.1177/1756287216638592. Epub 2016 Mar 15.

No abstract available.

Cite
Altez-Fernandez C, Seas C, Zegarra L, et al. Diseases masking and delaying the diagnosis of urogenital tuberculosis. Ther Adv Urol. 2016;8(3):234doi: 10.1177/1756287216638592.
Altez-Fernandez, C., Seas, C., Zegarra, L., & Ugarte-Gil, C. (2016). Diseases masking and delaying the diagnosis of urogenital tuberculosis. Therapeutic advances in urology, 8(3), 234. https://doi.org/10.1177/1756287216638592
Altez-Fernandez, Carlos, et al. "Diseases masking and delaying the diagnosis of urogenital tuberculosis." Therapeutic advances in urology vol. 8,3 (2016): 234. doi: https://doi.org/10.1177/1756287216638592
Altez-Fernandez C, Seas C, Zegarra L, Ugarte-Gil C. Diseases masking and delaying the diagnosis of urogenital tuberculosis. Ther Adv Urol. 2016 Jun;8(3):234. doi: 10.1177/1756287216638592. Epub 2016 Mar 15. PMID: 27247632; PMCID: PMC4872192.
Copy Download .nbib Format: NLM
Malignancy after gastrointestinal augmentation in childhood.

Therapeutic advances in urology

Husmann DA.
PMID: 21789049
Ther Adv Urol. 2009 Apr;1(1):5-11. doi: 10.1177/1756287209104163.

INTRODUCTION: To review the incidence and risks of bladder cancer following gastrointestinal augmentations done for congenial anomalies in childhood.MATERIALS AND METHODS: A literature search using PubMed and Ovid Medline search engines was performed. MeSH terms evaluated were; bladder augmentations,...

Cite
Husmann DA. Malignancy after gastrointestinal augmentation in childhood. Ther Adv Urol. 2009;1(1):5-11doi: 10.1177/1756287209104163.
Husmann, D. A. (2009). Malignancy after gastrointestinal augmentation in childhood. Therapeutic advances in urology, 1(1), 5-11. https://doi.org/10.1177/1756287209104163
Husmann, Douglas A. "Malignancy after gastrointestinal augmentation in childhood." Therapeutic advances in urology vol. 1,1 (2009): 5-11. doi: https://doi.org/10.1177/1756287209104163
Husmann DA. Malignancy after gastrointestinal augmentation in childhood. Ther Adv Urol. 2009 Apr;1(1):5-11. doi: 10.1177/1756287209104163. PMID: 21789049; PMCID: PMC3126046.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 453 entries